Back

Betrixaban versus enoxaparin for venous thromboembolism prophylaxis in critically ill patients: findings from the APEX trial

27 August 2018 (17:31 - 17:45)
Organised by:
Congress Presentation Part of: Progress in anticoagulation for venous thromboembolism Venous Thromboembolism ESC Premium Access ESC Congress 2018

About the speaker

Photo
Doctor Arzu KALAYCI

Harvard Medical School, Boston (United States of America)

3 More presentations in this session

Presentation thumbnail
State of the Art - Optimizing the prevention of venous thromboembolism
Professor A. Spyropoulos (New York, US)
Slides Video
Presentation thumbnail
Asian patients versus non-Asian patients in the efficacy and safety of direct oral anticoagulants relative to vitamin K antagonist for venous thromboembolism: a systemic review and meta-analysis
Doctor Y. Yamashita (Kyoto, JP)
Abstract Slides Video
Presentation thumbnail
Predictive value of VTE-BLEED to predict major bleeding and other adverse events in a practice-based cohort of patients with venous thromboembolism: results of the XALIA study
Doctor E. Klok (Leiden, NL)
Abstract

Access the full session

Session thumbnail
Progress in anticoagulation for venous thromboembolism

The Event

Event poster

ESC Congress 2018

27 August 2018 17:31 CET

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources